Home>>Signaling Pathways>> Others>>Rituximab (Anti-Human CD20 type I, Chimeric Antibody)

Rituximab (Anti-Human CD20 type I, Chimeric Antibody) (Synonyms: IDEC-C2B8)

Catalog No.GC34209

Rituximab (Anti-Human CD20 type I, Chimeric Antibody) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.

Products are for research use only. Not for human use. We do not sell to patients.

Rituximab (Anti-Human CD20 type I, Chimeric Antibody) Chemical Structure

Cas No.: 174722-31-7

Size Price Stock Qty
1mg
$202.00
In stock
5mg
$404.00
In stock
25mg
$2,023.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product Documents

Quality Control & SDS

View current batch:

Protocol

Cell experiment [1]:

Cell lines

Peripheral blood mononuclear cells from B-CLL patients

Preparation Method

7×104 cells/well were plated in quadruplicate in 96-well plates in the presence or absence of 0.3-1µg/ml fludarabine. After 24 h, human serum was added to a final 25% in the presence or absence of 10 µg/ml rituximab and the cells incubated for 4 h at 37°C.

Reaction Conditions

10 µg/ml for 4 hours

Applications

In CLL 4, rituximab and complement alone induced 34% cell death.

Animal experiment [2]:

Animal models

Male C57BL/6 mice, weighing 18-22 g,

Preparation Method

Each animal received a single injection of rituximab (10 mg/mL) by either IV (1 and 40 mg/kg; tail vein) or SC routes (1, 10 and 40 mg/kg; mid back or mid abdomen). The volume of injection was 4 mL/kg (80 µL for 20 g mouse), and the commercially available formulation (10 mg/mL) was diluted with sterile normal saline for low doses.

Dosage form

IV for 1, 40 mg/kg and SC for 1, 10, 40 mg/kg

Applications

The Subcutaneous (SC) absorption of rituximab in mice shows at both tested injection sites (back and abdomen), the extent of absorption was inversely related to the dose level, the absorption of rituximab from the abdomen was faster than at the back.

References:

[1]: Di Gaetano, N. et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the, cytotoxic activity of either drug alone. Br. J. Haematology 114, 800-809 (2001).
[2]: Kagan L, Zhao J, Mager DE . Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats. Pharm Res 2014; 31: 3265-3273.

Background

Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma [1].

Intravenously administered rituximab was granted regulatory approval in 1997 by the US Food and Drug Administration and in 1998 by the European Medicines Agency for use in relapsed/refractory indolent non-Hodgkin lymphomas. Approvals for use in chronic lymphocytic leukemia followed in 2009 and 2010, respectively [1].

Rituximab binds with high affinity and specificity to the CD20 antigen, which is expressed on the vast majority of malignant B cells. The apparent affinity constant of rituximab for human CD20, as determined by Scatchard analysis using a human lymphoblastoid cell line, is approximately 5.2 nmol/L [2]. Rituximab provides significant, clinically meaningful benefits to patients with active rheumatoid arthritis also. In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotrexate, provided significant improvement in disease symptoms at both weeks 24 and 48 [3].

References:
[1]. Salles G, Barrett M, FoÀ R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232-2273.
[2]. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-45.
[3]. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581

Chemical Properties

Cas No. 174722-31-7 SDF
Synonyms IDEC-C2B8
Canonical SMILES [Rituximab]
Formula C6416H9874N1688O1987S44 M.Wt 144544.44
Solubility Storage Store at -80°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 0.0069 mL 0.0346 mL 0.0692 mL
5 mM 0.0014 mL 0.0069 mL 0.0138 mL
10 mM 0.0007 mL 0.0035 mL 0.0069 mL
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Reviews

Review for Rituximab (Anti-Human CD20 type I, Chimeric Antibody)

Average Rating: 5 ★★★★★ (Based on Reviews and 33 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Rituximab (Anti-Human CD20 type I, Chimeric Antibody)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.